Pozzilli C, Koudriavtseva T
Dipartimento di Scienze Neurologiche, I Clinica Neurologica, Università di Roma La Sapienza, Italy.
Baillieres Clin Neurol. 1997 Oct;6(3):481-93.
An improved understanding of the immunopathogenesis of multiple sclerosis (MS) has led to therapeutic attempts using immunoregulatory agents in patients with MS, including interferon beta. IFN-beta 1a has been tested in relapsing-remitting MS and its effectiveness in reducing exacerbation rate and in slowing sustained worsening of disability after 2 years has been shown. Magnetic resonance imaging results supported the clinical findings, showing a significant reduction in Gd-enhancing lesion frequency and new lesion formation on T2-weighted images. This type of interferon is well tolerated and most adverse events are mild and transient. Further trials are in progress to amplify and clarify the observed benefits of IFN-beta 1a.
对多发性硬化症（MS）免疫发病机制的深入了解促使人们尝试在MS患者中使用免疫调节药物，包括干扰素β。干扰素β1a已在复发缓解型MS中进行了测试，结果显示其在降低发作率以及减缓两年后残疾持续恶化方面具有有效性。磁共振成像结果支持了临床发现，显示钆增强病变频率显著降低，且在T2加权图像上新病变形成减少。这类干扰素耐受性良好，大多数不良事件轻微且短暂。进一步的试验正在进行中，以扩大并明确观察到的干扰素β1a的益处。
